摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

甲基(1R,2S,3S,5S)-3-(4-氟苯基)-8-甲基-8-氮杂双环[3.2.1]辛烷-2-甲酸酯 | 50370-56-4

中文名称
甲基(1R,2S,3S,5S)-3-(4-氟苯基)-8-甲基-8-氮杂双环[3.2.1]辛烷-2-甲酸酯
中文别名
(1R,2S,3S,5S)-3-(4-氟苯基)-8-甲基-8-氮杂双环[3.2.1]辛烷-2-甲酸甲酯;(-)-2-Beta-羰基甲氧基-3-beta-(4-氟苯基)托烷
英文名称
2β-carbomethoxy-3β-(4-fluorophenyl)tropane
英文别名
Win 35428;[1R-(exo,exo)]-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid methyl ester;[3H]-WIN35428;CFT;β-CFT;(1R)-N-methyl-2β-methoxycarbonyl-3β-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane;methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
甲基(1R,2S,3S,5S)-3-(4-氟苯基)-8-甲基-8-氮杂双环[3.2.1]辛烷-2-甲酸酯化学式
CAS
50370-56-4
化学式
C16H20FNO2
mdl
——
分子量
277.339
InChiKey
QUSLQENMLDRCTO-YJNKXOJESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    91-92℃
  • 沸点:
    349℃
  • 密度:
    1.155
  • 闪点:
    165℃
  • 溶解度:
    可溶于水中

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    T+
  • 安全说明:
    S22,S26,S36/37/39,S45
  • 危险类别码:
    R26/27/28,R62,R43
  • 危险品运输编号:
    UN 1544 6

SDS

SDS:f086aa39f493cd5fbf04c7c2767f54ce
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    甲基(1R,2S,3S,5S)-3-(4-氟苯基)-8-甲基-8-氮杂双环[3.2.1]辛烷-2-甲酸酯溶剂黄146 、 potassium iodide 、 作用下, 以 乙醇甲苯 为溶剂, 反应 33.0h, 生成 甲基(1R,2S,3S,5S)-3-(4-氟苯基)-8-丙-2-烯基-8-氮杂双环[3.2.1]辛烷-2-羧酸酯
    参考文献:
    名称:
    Synthesis and receptor binding of N-substituted tropane derivatives. High-affinity ligands for the cocaine receptor
    摘要:
    The synthesis and pharmacological characterization of a series of N-substituted 3-(4-fluorophenyl)tropane derivatives is reported. The compounds displayed binding characteristics that paralleled those of cocaine, and several had substantially higher affinity at cocaine recognition sites. Conjugate addition of 4-fluorophenyl magnesium bromide to anhydroecgonine methyl ester gave 2-beta-(carbomethoxy)-3-beta-(4-fluorophenyl)tropane (4a, designated CFT, also known as WIN 35,428) after flash chromatography. N demethylation of 4a was effected by Zn/HOAc reduction of the corresponding 2,2,2-trichloroethyl carbamate to give 2-beta-carbomethoxy-3-beta-(4-fluorophenyl)nortropane (5), which was alkylated with allyl bromide to afford the N-allyl analogue, 6. The N-propyl analogue, 7, was prepared by catalytic reduction (Pd/C) of 6. The most potent analogue, 4a, was tritiated at a specific activity of 81.3 Ci/mmol. [H-3]4a bound rapidly and reversibly to caudate putamen membranes; the two-component binding curve typical of cocaine analogues was observed. Equilibrium was achieved within 2 h and was stable for at least 4 h. High- and low-affinity K(d) values observed for [H-3]4a (4.7 and 60 nM, respectively) were more than 4 times lower than those for [H-3]cocaine, and the density of binding sites (B(max) = 50 pmol/g, high, and 290 pmol/g, low) for the two drugs were comparable. Nonspecific binding of [H-3]4a was 5-10% of total binding.
    DOI:
    10.1021/jm00109a029
  • 作为产物:
    参考文献:
    名称:
    7-氮杂三环癸烷的设计,合成和生物学评估:可卡因类似物。
    摘要:
    描述了一系列可卡因的氮杂三环癸烷类似物的合成和生物活性。本系列研究的所有化合物对血清素转运蛋白和多巴胺转运蛋白均具有纳摩尔效价和良好的选择性。
    DOI:
    10.1016/s0960-894x(99)00685-x
点击查看最新优质反应信息

文献信息

  • Synthesis and Biological Properties of New 2β-Alkyl- and 2β-Aryl-3-(substituted phenyl)tropane Derivatives:  Stereochemical Effect of C-3 on Affinity and Selectivity for Neuronal Dopamine and Serotonin Transporters
    作者:Alan P. Kozikowski、Gian Luca Araldi、K. R. C. Prakash、Mei Zhang、Kenneth M. Johnson
    DOI:10.1021/jm9802564
    日期:1998.12.1
    present work is a 2, 3-diaryltropane 22 in a boat conformation that is highly selective (69-fold) for the DAT over the 5HTT. The ability to prepare this compound as well as related structures by our oxidopyridinium betaine-based dipolar cycloaddition strategy further underscores the versatility of this particular chemical approach to the preparation of diverse tropane analogues. The use of the optically
    在努力确定可能充当可卡因拮抗剂或可卡因部分激动剂的分子的过程中,我们参与了通过结构上的战略性修饰来进一步阐明可卡因与多巴胺转运蛋白(DAT)结合的性质的努力。在取代基位于托环环的2位的情况下,研究表明转运蛋白能够容纳多种结构的基团,包括酯,酮,烷基,烯基,杂环和芳基取代基,而不会损失DAT绑定亲和力。在本研究中,我们报告了有关DAT容纳WIN型结构的能力的结果,该结构在2位具有烷基或芳基,并且采用了环烷的椅子或船形。而且,我们讨论了这些化合物的立体化学对DAT相对于血清素转运蛋白(5HTT)的选择性的影响。此外,我们指出了在进行转运蛋白选择性的比较时,使用Ki值而不是IC50值的重要性。在本研究中鉴定出的最有趣的化合物之一是船形的2,3-二芳基托烷22,它对DAT的选择性比5HTT高(69倍)。通过我们基于氧化吡啶鎓甜菜碱的偶极环加成策略制备该化合物及相关结构的能力进一步强调了这种特殊化学
  • Tropane analogs and methods for inhibition of monoamine transport
    申请人:——
    公开号:US20030105125A1
    公开(公告)日:2003-06-05
    New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    描述了结合到单胺转运体的新的曲梯酮类似物,特别是8-氮杂、8-羰基和8-酮基曲梯酮,具有6-或7-羟基或酮基取代基。本发明的化合物可以是外消旋体、纯R-对映体或纯S-对映体。本发明的某些优选化合物对DAT与SERT具有很高的选择性。还描述了包含所述化合物的药用治疗组合物,其配制在药用可接受载体中,并通过将所述单胺转运体与本发明的化合物的5-羟色胺再摄取抑制量接触的方法来抑制单胺转运体的5-羟色胺再摄取。本发明实施的首选单胺转运体包括多巴胺转运体、5-羟色胺转运体和去甲肾上腺素转运体。
  • [EN] BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS, COMPOSÉS BOLAAMPHIPHILES, ET LEURS UTILISATIONS
    申请人:LAUREN SCIENCES LLC
    公开号:WO2016168580A1
    公开(公告)日:2016-10-20
    Bolaamphiphilic compounds are provided according to formula (I); where HG1, HG2 and L1 are as defined herein. Provided bolaamphiphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into animal or human brain.
    根据公式(I),提供了双亲嵌段化合物;其中HG1、HG2和L1如本文所定义。提供的双亲嵌段化合物及其制成的药物组合物可用于将GDNF或NGF输送到动物或人类大脑中。
  • Preparation of [18F]β-CFT-FP and [11C]β-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET)
    作者:Eeva-Liisa Kämäräinen、Teija Kyllönen、Anu Airaksinen、Camilla Lundkvist、Meixiang Yu、Kjell Någren、Johan Sandell、Oliver Langer、Jouko Vepsäläinen、Jukka Hiltunen、Kim Bergström、Simo Lötjönen、Timo Jaakkola、Christer Halldin
    DOI:10.1002/1099-1344(20001030)43:12<1235::aid-jlcr411>3.0.co;2-9
    日期:2000.10.30
    congener β-CFT (I), N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-fluorophenyl)nortropane (β-CFT-FP, III), was labelled with 18F or 11C. Syntheses of the precursors nor-β-CFT (II) and β-CFT-FP acid (IV) as well as III itself are described. [18F]β-CFT-FP was prepared starting from I using two different labelling reagents: [18F]fluoropropyl bromide (V) and [18F]fluoropropyl tosylate (VI). A reversed-phase HPLC system
    在本研究中,可卡因同系物 β-CFT (I)、N-(3-氟丙基)-2β-carbomethoxy-3β-(4-fluorophenyl)nortropane (β-CFT-FP, III) 的 N-氟丙基类似物是标有 18F 或 11C。描述了前体 Nor-β-CFT (II) 和 β-CFT-FP 酸 (IV) 以及 III 本身的合成。[18F]β-CFT-FP 是从 I 开始使用两种不同的标记试剂制备的:[18F] 氟丙基溴 (V) 和 [18F] 氟丙基甲苯磺酸酯 (VI)。反相 HPLC 系统被证明可以有效地将标记产物与前体 II 分离。V或VI的放射化学掺入产生[18F]β-CFT-FP(18F-III)一般为30-50%,放射化学纯度高于99%。[11C]β-CFT-FP (11C-III) 通过使用 [11C] 三氟甲磺酸甲酯 (VII) 的 IV 酯化合成。事实证明,使用反相柱的
  • Therapeutic compounds
    申请人:——
    公开号:US20030232827A1
    公开(公告)日:2003-12-18
    This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The invention also relates to compounds that differentially prevent transport or binding through a transporter or to a receptor. The invention also relates to the use of these compounds for treating certain diseases and disorders.
    这项发明涉及抑制转运体和受体的拮抗剂。该发明还涉及部分抑制剂,允许化合物部分转运或部分结合到转运体或受体。该发明还涉及不同程度地阻止通过转运体或受体的转运或结合的化合物。该发明还涉及利用这些化合物治疗某些疾病和疾病。
查看更多